Zydus Cadila Launches Ujvira, First Antibody Drug Conjugate (ADC) Breast Cancer Treatment

Trastuzumab Emtansine ADC biosimilar is developmental breakthrough due to its complexity in manufacturing and similarity assays.

Zydus Cadila has launched Trastuzumab Emtansine, the first antibody Drug Conjugate (ADC) biosimilar for early and advanced HER2 positive Breast Cancer Patients’ treatment.

The drug has been launched under the brand name ‘Ujvira’, and will be available in two strengths, 100 mg and 160 mgand.

It has been priced at Rs. 32495 for a 100 mg vial.

As per the claims made by the company, ‘Ujvira’ has been priced at nearly 80 percent less than the market price.

“Trastuzumab Emtansine ADC biosimilar is developmental breakthrough due to its complexity in manufacturing and similarity assays. This drug is made by combining Trastuzumab and a cytotoxic compound Emtansine (DM1) with the help of a stable linker by a process called Antibody Drug Conjugation. Due to this technology the targeted delivery of the cytotoxic agent is enabled and the other toxicities on body are reduced,” said the company.

Speaking on the launch, Dr. Sharvil Patel, Managing Director, Cadila Healthcare Limited said, “The launch of Ujvira reinforces the innovation capabilities that India has to be able to create complex therapies like ADCs and Zydus’ ongoing commitment to offer breakthroughs backed by science and innovation. This research breakthrough enables access to a critical drug for patients who are undergoing therapy for Breast Cancer. We hope that with this innovation, patients will be able to adhere to the treatment and stand to benefit from the advanced technology without worrying about the cost of the treatment.”

Facebook Comments